Why the study?
Does EGFR activation mediate mechanical strain-dependent stimulation of the hBNP promoter in cardiac hypertrophy models?
Does EGFR activation mediate mechanical strain-dependent stimulation of the hBNP promoter in cardiac hypertrophy models?
Metalloproteinase-dependent cleavage of pro-HBEGF and subsequent EGFR activation is an essential pathway in mechanical strain-induced cardiac hypertrophy, representing a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
May link EGFR to strain-induced hypertrophy signaling; leaves open therapeutic relevance in human disease.
The epidermal growth factor receptor (EGFR) and ectoshedding of heparin-binding epidermal growth factor (HBEGF), an EGFR ligand, have been linked to the development of cardiac myocyte hypertrophy. However, the precise role that the liganded EGFR plays in the transcriptional activation of the gene program that accompanies hypertrophy remains undefined. Utilizing the human (h) BNP gene as a model of hypertrophy-dependent gene activation, we show that activation of the EGFR plays an important role in mediating mechanical strain-dependent stimulation of the hBNP promoter. Strain promotes endothelin (ET) generation through NAD(P)H oxidase-dependent production of reactive oxygen species. ET in turn induces metalloproteinase-mediated cleavage of pro-HBEGF and ectoshedding of HBEGF, which activates the EGFR and stimulates hBNP promoter activity. HBEGF also stimulates other phenotypic markers of hypertrophy including protein synthesis and sarcomeric assembly. The antioxidant N-acetylcysteine or the NAD(P)H oxidase inhibitor, apocynin, inhibited strain-dependent activation of the ET-1 promoter, HBEGF shedding, and hBNP promoter activation. The metalloproteinase inhibitor, GM-6001, prevented the induction of HBEGF ectoshedding and the hBNP promoter response to strain, suggesting a critical role for the metalloproteinase-dependent cleavage event in signaling the strain response. These findings suggest that metalloproteinase activity as an essential step in this pathway may prove to be a relevant therapeutic target in the management of cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: